Related Experiment Video
Updated: Feb 13, 2026

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
Published on: February 12, 2021
MicroRNA 26a Expression in Peripheral Blood Mononuclear Cells and Correlation with Serum Interleukin-17 in
Fatma M Mahmoud1, Nadia M ElSheshtawy1, Wafaa K Zaki1
1Department of Medical Microbiology & Immunology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Abstract:
Multiple sclerosis (MS) is a chronic multifocal inflammatory demyelinating disease. One of the main cells that play a crucial role in pathogenesis of MS is T helper 17 (Th 17). There are growing interests in nominating microRNAs in Th17 cell differentiation and suggesting new therapeutic modalities. The aim of the study was to assess microRNA 26a (miR26a) expression in peripheral blood mononuclear cells of relapsing - remitting MS patients as compared to healthy control subjects and examine association of these levels with serum IL17. Forty (40) relapsing - remitting MS patients were enrolled based on the MacDonald criteria (20 in relapsing phase and 20 in remitting phase). In addition, twenty (20) healthy control subjects were included. Blood samples were subjected to quantitative polymerase chain reaction (qPCR) for miR26a and ELISA for serum IL 17 levels. A significant upregulation of miR26a relative expression level (∆∆ Ct) and serum IL17 level (pg/ml) was found in total MS patients and remitting MS patients when compared with controls (P < 0.001). Among the relapsing group, a significant increase in miR26a expression levels (P= 0.004) but not serum IL17 level was demonstrated. Insignificant correlation between miR26a expression and serum IL17 in MS patients was detected (r= 0.08, P= 0.62). In conclusion, a significant increase of these two biomarkers (miR26a & IL17) occurs in relapsing - remitting MS patients, and this reflects their important role in pathogenesis and disease development.
Insights
This study found increased levels of microRNA 26a (miR26a) and Interleukin 17 (IL17) in patients with relapsing-remitting multiple sclerosis (MS). These biomarkers may play a role in MS pathogenesis.
Area of Science:
- Neuroimmunology
- Molecular Biology
Background:
- Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease.
- T helper 17 (Th17) cells are key players in MS pathogenesis.
- MicroRNAs are increasingly recognized for their role in Th17 cell differentiation and potential therapeutic applications.
Purpose of the Study:
- To investigate microRNA 26a (miR26a) expression in peripheral blood mononuclear cells of relapsing-remitting MS patients.
- To compare miR26a levels with healthy controls.
- To examine the association between miR26a levels and serum Interleukin 17 (IL17) in MS patients.
Main Methods:
- Quantitative polymerase chain reaction (qPCR) was used to measure miR26a expression.
- Enzyme-linked immunosorbent assay (ELISA) was employed to determine serum IL17 levels.
- Forty relapsing-remitting MS patients and twenty healthy controls were included in the study.
Main Results:
- A significant upregulation of miR26a and IL17 was observed in total MS patients and those in the remitting phase compared to controls (P < 0.001).
- The relapsing MS group showed a significant increase in miR26a expression (P= 0.004) but not IL17 levels.
- No significant correlation was found between miR26a expression and serum IL17 levels in MS patients (r= 0.08, P= 0.62).
Conclusions:
- Both miR26a and IL17 are significantly elevated in relapsing-remitting MS patients.
- These findings suggest that miR26a and IL17 are important biomarkers in the pathogenesis and development of MS.
Related Concept Videos
MicroRNAs
MicroRNAs
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Regulation of Expression Occurs at Multiple Steps
Regulation of Expression at Multiple Steps
Cell Specific Gene Expression

